Healthy, Insulin Resistance
Conditions
Brief summary
The purpose of this study is to define the effect of ultrasound exposure of the liver in the region of the porta hepatis on glucose homeostasis and insulin resistance in healthy subjects.
Interventions
PROCEDUREUltrasound
To determine whether ultrasound exposure at the porta hepatis will affect plasma glucose levels. To also determine whether porta hepatic ultrasound exposure will affect plasma glucose levels as well as insulin sensitivity among overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance (as defined by OGTT.
Sponsors
GE Healthcare
Yale University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* 18 - 60 years of age * Aim 1: Healthy lean men and women, BMI\<24 kg/m2, with normal fasting glucose (blood glucose between 60 and 100mg/dl and normal glucose tolerance on OGTT (blood glucose \<140 mg/dl at 2 hours post glucose challenge) at the screening visit. * Aim 2: Overweight and obese men and women, BMI 25 - 35 kg/m2
Exclusion criteria
* Type 1 and type 2 diabetes * Surgery in the past 90 days * Previous surgery of the spleen or splenectomy, esophagus, lungs, stomach, duodenum, or liver * Recent traumatic injury, including intra-cerebral hemorrhage and visceral injury * End stage renal disease and/or uremia * Active malignancy * Previous leukemia and/or lymphoma * Human immunodeficiency virus infection or AIDS * Rheumatoid arthritis or other immune-mediated diseases (e.g. inflammatory bowel disease) * Arrhythmias, including but not limited to, atrial fibrillation, atrial flutter, bradycardia, ventricular arrhythmias, and A-V block * Implanted pacemaker or cardioverter/defibrillator (AICD) * History of stable or unstable angina, myocardial infarction, angioplasty or coronary arterial by-pass grafting surgery * History of stroke or TIA * History of deep venous thrombosis (DVT) and/or pulmonary embolism (PE) * Previous episodes of pancreatitis * Spinal disorders * Chronic pain syndromes * History of thrombosis or bleeding disorders * Stage III-IV pressure ulcers * Sickle cell anemia or other anemia syndromes * Monocytosis * Thrombocytopenia * Diagnosed with fever of unknown origin (FUO) * Previously or currently implanted vagus nerve stimulator * Previously or currently implanted spinal cord stimulator * Other chronically-implanted electronic medical device * History of seizures * History of cancer * Individuals who have taken any of the following medications within two weeks of receiving ultrasound delivery: anti-coagulant, anti-platelet, anti-inflammatory, immunosuppressive agents, alpha and/or beta adrenoceptor blocking agents, anti-seizure medications, anti-diabetic medication * Individuals with a substance abuse problem * Pregnant women * Ascites detected in the abdomen that may effect delivery of shear wave elastroghapy pulse
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Insulin Resistance | 1 week | Change in OGTT measurements after Hepatic Ultrasound |
Countries
United States
Outcome results
None listed